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Background: We describe the case of a young woman with seasonal allergic rhinitis who 
presented with signs of a lower respiratory tract infection, acute renal impairment and the 
nephrotic syndrome, demonstrated on biopsy to be due to minimal change disease (MCD) 
with acute tubular injury. Following initiation of high-dose corticosteroids, her respiratory 
symptoms and renal impairment improved, and the nephrotic syndrome went rapidly into 
remission, but relapsed, off treatment, in a seasonal fashion.  
Management: In view of significant side effects related to corticosteroids, relapses were 
treated with the calcineurin inhibitor tacrolimus with excellent effect, but the patient was 
keen to avoid the complications of medium-term immunosuppression and so the drug was 
weaned early. She relapsed for the second time, whilst off tacrolimus, at the same time of 
year as at her initial presentation. In subsequent years we have successfully managed this 
patient with seasonal relapsing MCD with seasonal prophylactic tacrolimus therapy.  
Discussion: We discuss the natural history of MCD and treatment options and demonstrate 
the utility of a clear understanding of the natural history of the condition in order to predict 
disease relapse and tailor therapy to the individual patient. 
 
Case Report 
A 25-year-old Nigerian female pharmacist was admitted to our institution in June 2006 from a 
local hospital with the nephrotic syndrome. Two weeks prior to admission, she had been diagnosed 
with a lower respiratory tract infection and commenced on a 1-week course of amoxicillin. Two days 
after completing the antibiotic course, she noted oedema and oliguria. She presented to a local 
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hospital which noted moderate renal impairment and proteinuria. She was transferred to our 
institution for assessment, diagnosis and treatment. 
She had been in the United Kingdom for 10 years, had a past history of Malaria and took 
fexofenadine 120 mg once daily for prophylaxis of seasonal allergic rhinitis. She was allergic to 
chloroquine. 
Physical examination revealed fluid overload and haemodynamic stability (blood pressure 118/75 
mm Hg). Auscultation of the praecordium revealed normal heart sounds. Coarse crackles were noted 
at the right lung base. Abdomen was soft and non-tender. Urinalysis revealed 4+ protein and 4+ blood. 
Biochemical analysis revealed severe, and progressive, renal impairment, hypoalbuminaemia and 
hypercholesterolaemia. The urinary protein:creatinine ratio (PCR) was 2,377 mg/mmol (table 1). 
Immunological tests, including complement and lupus serology, were normal, or negative. 
Chest radiograph was clear and a renal ultrasound scan showed normal sized, unobstructed 
kidneys (right 10.5 cm, left 11.0 cm). Doppler examination of the renal vessels excluded a renal vein 
thrombosis. 
Renal biopsy (fig. 1) was obtained with an 18-gauge automatic spring loaded needle from the 
lower pole of the left kidney. Light and electron microscopy were performed. Light microscopy 
findings were of normal glomeruli and juxtaglomerular apparatus. The vessels were normal. 
Examination of the tubules revealed many with vacuolation of epithelial cell cytoplasm. Some tubules 
showed epithelial cell detachment and mitoses were present. Immunoperoxidase staining showed 
mesangial IgM+ and C1q+. Electron microscopy showed patent capillary loops lined by normal 
endothelium. There was a slight increase in mesangial matrix but no electron dense deposits. There 
was extensive effacement of the podocyte foot processes. 
The histopathological diagnosis was consistent with minimal change disease (MCD) with 
associated acute tubular damage which was sufficient to explain the renal dysfunction at 
presentation. 
The patient was commenced on corticosteroids (prednisolone 60 mg once daily) along with 
bumetanide 2 mg once daily; alfacalcidol 0.25 μg once daily; enoxaparin 10 mg subcutaneously once 
daily; lansoprazole 30 mg once daily; atorvastatin 40 mg every night; cetirizine 10 mg once daily and 
nystatin 1 ml four times a day. Renal function improved within days and she was discharged to 
outpatient follow-up. 
Complete remission was achieved 4 weeks after presentation (albumin >34 g/l and urinary PCR 
<50 mg/mmol), but the patient experienced psychological disturbance on high-dose corticosteroids, 
including mania, insomnia, irrationality and inappropriate thought and speech. The dose of 
corticosteroid was halved with improvement in psychological symptoms. Over the next few weeks, 
she put on flesh weight and dual energy X-ray absorptiometry revealed osteopenia of the lumbar 
spine. A bisphosphonate was added to her therapy. After completing 6 months of high-dose steroids, 
the dose of prednisone was weaned to zero over 4 months finishing in April. 
In June 2007, she developed respiratory symptoms, a productive cough and wheeze. She was not 
clinically nephrotic, but biochemical investigation confirmed relapse of the nephrotic syndrome with 
albumin 31 g/l, hypogammaglobulinaemia and urinary PCR of 779 mg/mmol. After discussion with 
the patient, she was treated with the calcineurin inhibitor tacrolimus. Initially, the patient was 
concerned about the risk of diabetes but agreed that tacrolimus was a superior option to long-term 
corticosteroids because she had already developed undesirable side effects (i.e. osteopenia, striae and 
transient psychological disturbance). She was commenced on tacrolimus 3 mg twice daily aiming for 
12-hour trough levels of 4–6 ng/ml (by liquid chromatography mass spectrometry method) and 
within 4 weeks had again achieved a complete remission. 
The patient’s work as a pharmacist gave her an unusual insight into the treatment of her condition , 
and she was concerned about potential hazards of long-term tacrolimus, and so after 6 months of 
therapy, we agreed to wean the dose of tacrolimus by 2 mg per month whilst warning the patient that 
we would normally treat for a longer duration and that she would be putting herself at risk of relapse. 
The patient discontinued tacrolimus in April 2008. 
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In June 2008, the patient presented with the symptoms of a chest infection, treated for 1 week in 
the community with penicillin V with no effect. On this occasion, she was clinically and biochemically 
nephrotic. In view of her previous rapid and sustained response to tacrolimus, this drug was 
recommenced at a dose of 4 mg twice daily. Complete remission was again achieved after 4 weeks.  
In view of the remarkably regular relapsing nature of this patient’s nephrotic syndrome, 
presenting with respiratory symptoms, on a background of seasonal allergic rhinitis, we thought it 
most likely that disease relapses were related to atopy, rather than to the discontinuation of 
immunosuppression 2 months previously. Given her rapid response to treatment and the patient’s 
reluctance to take long-term immunosuppression, we formulated a plan to give the patient tacrolimus 
during the summer months (between March and September). In March 2009, the patient electively 
commenced prophylactic tacrolimus 2 mg twice daily, and this was up-titrated to achieve a trough 
level of 3.0 ng/ml by June 2009. In June 2009, the patient again experienced symptoms of a lower 
respiratory tract infection, but the urinary PCR never rose above 15 mg/mmol and albumin was 
maintained at 41 g/l. Tacrolimus was rapidly weaned in October 2009 and the seasonal approach to 
immunosuppression was repeated in 2010 and 2011. The patient has not experienced a relapse of 
MCD to date (fig. 2). 
At the most recent follow-up (March 2012), the patient had normal renal function and albumin, 
and had undetectable levels of urinary protein excretion (table 1). We plan to continue this successful 
strategy for the foreseeable future. 
Discussion 
MCD is a common cause of the nephrotic syndrome in adults, after membranous 
glomerulonephropathy and focal segmental glomerulosclerosis [1]. The incidence of 
MCD is said to vary from 1 to 27 per million population. The aetiology of MCD is not 
fully understood, but the disease has been clearly associated with lymphomas, non-
steroidal anti-inflammatory drugs, and of particular relevance in this patient, appears 
to be more common in atopic individuals [2] or may be genuinely idiopathic.  
The manifestations of the disease reflect a disorder of podocyte structure and 
function, the cause of which is uncertain. The Shalhoub hypothesis [3] suggests that 
there is a circulating permeability factor, caused by a disordered T cell compartment, 
and supporting evidence for this theory comes from the successful use of 
immunomodulatory therapy in the treatment of the disease [4]. 
No recent clinical trials exist of the treatment of MCD, although historical trials 
favour a daily dose of oral corticosteroids (over alternate day or intravenous 
corticosteroids) [5–7]. Other therapies are available: levimasole is commonly used in 
children; alkylating agents such as cyclophosphamide are effective but concerns exist 
about toxicity, potential for neoplastic change and infertility. The calcineurin inhibitors 
cyclosporin A [4] and tacrolimus [8] have also been used to good effect in frequently 
relapsing MCD, again most commonly in children. No clinical trial has yet been 
published investigating the use of tacrolimus to treat de novo MCD. The exact dose and 
duration of treatment (with either corticosteroids or calcineurin inhibitors) has not yet 
been established. MCD is often erroneously thought of as a benign disease; however, 
patients may present, as in this case, with acute kidney injury and it is a disease which 
commonly relapses such that patients may be repeatedly exposed to potentially toxic 
immunotherapy. 
The pattern of relapse in this atopic patient, namely during the allergic rhinitis 
season, suggests that there is an immunological trigger to her nephrotic syndrome akin 
 Case Rep Nephrol Urol 2012;2:102–107 
DOI: 10.1159/000341257 
Published online: 
July 24, 2012 







to a type 4 hypersensitivity reaction. It is tempting to suggest that the pollen to which 
the patient is allergic may share a common epitope with an antigen presented on the 
podocyte. Although less likely, it is possible that disease relapses were related to 
withdrawal of immunosuppression. Immunosuppression had been withdrawn 
approximately 2 months prior to each relapse. 
Despite the probable immune-mediated trigger, it is not clear that tacrolimus is 
directly influencing the immune response, by inhibiting IL-2 transcription, as she still 
suffered from rhinitis but did not develop the nephrotic syndrome. There is, however, 
recent evidence that tacrolimus acts to protect and repair the podocyte (by stabilising 
the actin cytoskeleton [9]), thus directly preventing podocyte damage sufficient to 
prevent proteinuria. 
An alternative strategy for this patient would have been to ask the patient to 
monitor for proteinuria with urine dipstick testing and commence tacrolimus in the 
event of developing proteinuria. Whilst this is certainly an option, the nephrotic 
syndrome can develop rapidly and may take 4 weeks or more to respond to 
immunotherapy. In addition, some patients with relapses of MCD may be difficult to 
treat and may require a combination of corticosteroids and tacrolimus, sometimes at 
high doses. Rather than react to the development of proteinuria (which is not a benign 
state resulting in acute kidney injury and a hypercoagulable state) we, with the 
patient’s informed consent, prefer a proactive approach. 
This case study reminds us of the lack of evidence-based medicine in the treatment 
of podocytopathies (such as MCD) but clearly demonstrates the usefulness of 
tacrolimus for MCD. By understanding the natural history of this patient’s disease, we 
hope we have been able to demonstrate an unorthodox but effective management 
strategy which, importantly, is acceptable to the patient, thereby promoting 
concordance with therapy, and minimises exposure to potentially toxic agents. The 




Table 1. Biochemical characteristics 
     









     
     
Sodium, mmol/l 132 137 137 138 
Potassium, mmol/l 3.8 3.9 4.3 4.8 
Urea, mmol/l 13.8 3.5 7.7 3.1 
Creatinine, µmol/l 233 82 99 60 
Albumin, g/l 18 14 17 38 
Total Cholesterol, mmol/l 7.4 6.3 7.9 4.3 
Urinary PCR, U 2,377 1,017 1,439 0 
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Fig. 1. Renal biopsy (electron microscopy) showing extensive fusion of the podocyte foot processes. 
 
 
Fig. 2. Top panel showing prednisolone (Pred) dose (mg/day) in black and tacrolimus (Tac) level 
(ng/ml) in grey. Bottom panel showing urinary PCR (uPCR) (mg/mmol). Note that there has been no 
significant proteinuria since commencing prophylactic seasonal tacrolimus in 2009. 
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